#Canada #Toronto #CAR-T therapy #mRNA Technology #LNP Technology

Webinar Overview

In the ever-evolving landscape of cancer treatment, the recent innovations in mRNA design and lipid nanoparticle (LNP) technology pave the way for groundbreaking advancements in in vivo CAR-T therapy. This upcoming webinar, hosted by Xtalks, promises to shed light on how these technological strides can enhance T cell engineering directly within the body, marking a significant shift from traditional ex vivo methods.

Key Topics Discussed

The webinar will delve into several vital aspects of CAR-T development, including:
1. CAR Construct Design: Understanding how the optimizations in RNA modifications can facilitate improved CAR expression, translating into more effective treatments.
2. Targeted LNP Approaches: Exploring innovative LNP formulations that aim to enhance the precision, potency, and safety of therapeutics administered directly in vivo.
3. RNA Enhancements: The incorporation of modified sequences that foster increased stability and efficiency of CAR mRNA.

Why This Matters

The efficient and precise delivery of CAR constructs is crucial for the effectiveness of CAR-T therapies. Current advancements enable a more streamlined manufacturing process which not only enhances the therapeutic window but additionally ensures tailored treatments for patients based on their specific cancer profiles.

The featured speaker, Mark Shulewitz, PhD, a Field Application Scientist at GenScript, will lead the session, providing insights into recent advancements that have propelled CAR-T therapy’s success in clinical settings. Participants will also learn about:

• - Modular "drop-in" CAR plasmids that revolutionize the construct design process by allowing easy swapping of antigen-binding domains for rapid customization.
• - Types of LNP technologies tailored specifically for T cell delivery, ensuring that CAR constructs reach their intended targets efficiently and effectively.

Cutting-Edge Design Innovations

Several cutting-edge innovations will be highlighted during the webinar:

• - Modified Poly(A) Tails: Enhancing transcript stability and increasing the translational efficiency essential for CAR effectiveness.
• - Internal Ribosome Entry Sites (IRES): These structures uniquely allow CAR expression to be limited to T cells, minimizing unintended off-target activation—a key concern in therapy applications.
• - Exosome-like and Spleen-Tropic LNPs: Engineered for optimal delivery to lymphoid tissues where T cells reside, significantly improving CAR expression overall.

Who Should Attend?

This webinar is geared toward researchers, clinicians, and professionals in the biotech and pharmaceutical sectors who are involved in CAR-T development or looking to gain insights into the latest methodologies transforming cancer treatments.
Participants will have the opportunity to engage in a Q&A session, facilitating meaningful interactions with the experts.

Registration Information

Don’t miss the chance to learn how these advanced technologies are reshaping the future of CAR-T therapy. Register today for the live webinar on November 5, 2026, at 11 AM EST (5 PM CET) to secure your spot.

For further details or to register, please visit the official Xtalks event page on advances in mRNA and LNP technology for CAR-T therapy.

Join the community of professionals advancing the science of cancer treatment, and be at the forefront of innovative healthcare solutions!

About Xtalks

Xtalks serves as a cornerstone for life science professionals, providing a host of resources including webinars, articles, and community engagement opportunities tailored towards empowering industry leaders and enhancing knowledge transfer.